Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases

Sandeep P. Kishore*, Evan Blank, David J. Heller, Amisha Patel, Alexander Peters, Matthew Price, Mahesh Vidula, Valentin Fuster, Oyere Onuma, Mark D. Huffman, Rajesh Vedanthan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations

Abstract

The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts.

Original languageEnglish (US)
Pages (from-to)564-574
Number of pages11
JournalJournal of the American College of Cardiology
Volume71
Issue number5
DOIs
StatePublished - Feb 6 2018

Funding

Dr. Kishore leads a partnership on multiple chronic conditions supported by the Arnhold Institute for Global Health and Teva Pharmaceuticals. Dr. Heller has been supported by the Fogarty International Center of the National Institutes of Health (award number R21 TW 010452-01); and has received research support from Teva Pharmaceuticals. Dr. Price has served as a consultant for Last Mile Health, which receives funding from Pfizer, Johnson & Johnson, and Medtronic. Neither Last Mile Health nor these funders played any role in this work. Dr. Huffman has been supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (award number R00 HL107749-05); and has received travel support from the World Heart Federation to attend a polypill meeting and to serve as its senior program advisor for the Emerging Leaders Programme, which is supported by Boehringer Ingelheim and Novartis and has been supported by AstraZeneca and Bupa. Dr. Vedanthan has been supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (award number 1R01HL125487-01A1). The content is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Gerald S. Bloomfield, MD, MPH, served as Guest Editor for this paper.

Keywords

  • NCDs
  • WHO Essential Medicines List
  • cardiovascular disease
  • essential medicines

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases'. Together they form a unique fingerprint.

Cite this